Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced four poster presentations at the Florida Society of Dermatology Physician Assistants (FSDPA) New Wave Dermatology Conference from April 28 to May 1, 2022. The presentations will include new clinical data on ARAZLO® (tazarotene) lotion for truncal acne, marking its first open-label clinical study for this condition. Additional data on DUOBRII®, JUBLIA®, and SILIQ® will also be shared, highlighting the company's commitment to advancing dermatological treatments.
Bausch Health (BHC) and Novaliq GmbH announced positive results from the pivotal Phase 3 trial (GOBI) for NOV03, a novel eye drop treatment for dry eye disease associated with Meibomian gland dysfunction. The study involved 597 participants and demonstrated that NOV03 met both primary endpoints: a significant decrease in total corneal fluorescein staining and improved eye dryness scores at day 57 (P0.001). The treatment was well tolerated with low adverse event rates. The companies plan to submit for FDA approval in Q2 2022, potentially addressing a significant unmet medical need.
Bausch + Lomb has achieved a significant milestone by recycling over 48 million units, equivalent to 290,145 pounds of contact lenses and related materials, through its ONE by ONE and Biotrue® Eye Care Recycling programs. These initiatives, launched in collaboration with TerraCycle, prevent waste from ending up in landfills. The ONE by ONE program has recycled over 48 million items since 2016, while the Biotrue® program has collected over 153,222 items since its launch in April 2021. Both programs highlight Bausch + Lomb's commitment to sustainability in eye health.
Bausch Health Companies Inc. (BHC) announced a planned separation of its eye health business, Bausch + Lomb, which intends to enter a new credit agreement. This agreement includes a $2.5 billion term loan and a $500 million revolving credit facility, both maturing in 2027. The funds from the term loan will be used to repay an intercompany note to Bausch Health following Bausch + Lomb's initial public offering. The completion of these transactions is subject to market conditions and other approvals, anticipated to close in Q2 2022.
Bausch Health (NYSE/TSX: BHC) announced the presentation of 10 podium and 2 poster presentations at the upcoming American Society of Cataract and Refractive Surgery annual meeting, from April 22-26, 2022, in Washington, D.C. Key highlights include results from the pivotal Phase 3 trial of NOV03, aimed at treating dry eye disease associated with Meibomian gland dysfunction. The trial results will be featured in a presentation titled "Efficacy of Perfluorohexyloctane on Signs and Symptoms of Dry Eye Disease: The Gobi Study." Bausch + Lomb aims to support surgeons with ongoing scientific exchange.
Salix Pharmaceuticals, part of Bausch Health Companies (BHC), announced it will present four research posters at the Society of Hospital Medicine (SHM) Converge 2022, held from April 7-10 in Nashville, TN. The featured studies cover XIFAXAN® (rifaximin) for hepatic encephalopathy and RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation. Key findings include XIFAXAN’s effectiveness in reducing emergency department visits and RELISTOR’s safety profiles. These presentations aim to enhance awareness of treatment options in gastroenterology.
Summary not available.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to reduce debt by $200 million by paying down senior secured term loans on March 31, 2022. This strategic move will be financed through cash generated from operations, demonstrating the company's commitment to improving its financial health. Bausch Health continues to focus on enhancing its portfolio in therapeutic areas such as eye health, gastroenterology, and dermatology.
Bausch Health and Clearside Biomedical announced the U.S. commercial launch of XIPERE®, the first FDA-approved therapy for suprachoroidal injection, designed to treat macular edema associated with uveitis. This therapy aims to address a serious condition affecting approximately 300,000 Americans, which can lead to vision loss. Key features include targeted delivery through the proprietary SCS Microinjector®, providing higher bioavailability and lower side effects compared to traditional methods. Training for eye care professionals on administration techniques is highlighted as crucial for successful implementation.
Bausch Health Companies (NYSE/TSX: BHC) announced a study demonstrating that FDA-approved medications for opioid-induced constipation (OIC), particularly RELISTOR®, significantly reduce hospitalization rates and costs. Research published in Advances in Therapy showed a 64% lower chance of hospitalization for OIC patients treated with OIC-Rx compared to those who were not. Furthermore, patients treated with RELISTOR had a reduction of $781 in healthcare costs per emergency department encounter. The study highlights the potential healthcare benefits and cost-effectiveness of using RELISTOR in OIC management.